Cyclopamine, an inhibitor of the SHH pathway, significantly reduces the percentage but does not impact the viability of CD133+ stem cells, while rapamycin does not affect the content of CD133+ cells but significantly reduces the overall viability of pancreatic cancer cells [86]. The gene discussed is PROM1; the disease is pancreatic neoplasm.